| 8.22 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.63 | 1-year : | 11.25 |
| Resists | First : | 8.25 | Second : | 9.63 |
| Pivot price | 8.22 | |||
| Supports | First : | 8.2 | Second : | 8.18 |
| MAs | MA(5) : | 8.22 | MA(20) : | 8.22 |
| MA(100) : | 7.42  |
MA(250) : | 6.04 |
|
| MACD | MACD : | 0.01  |
Signal : | 0.01 |
| %K %D | K(14,3) : | 57.14 | D(3) : | 57.14 |
| RSI | RSI(14): 73.52 | |||
| 52-week | High : | 8.25 | Low : | 4.01 |
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Thu, 18 Apr 2024
Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Movies UK
Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - GlobeNewswire
Tue, 26 Oct 2021
Adamas Pharmaceuticals Stock: An Acceptable Buyout At The Perfect Time (NASDAQ:ADMS) - Seeking Alpha
Mon, 11 Oct 2021
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - GlobeNewswire
Mon, 01 Mar 2021
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Business Wire
Wed, 24 Feb 2021
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 46 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 80.3 (%) |
| Shares Short | 1,600 (K) |
| Shares Short P.Month | 2,510 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | -1.17 |
| EPS Est This Year | -3.77 |
| EPS Est Next Year | -3.43 |
| Book Value (p.s.) | -0.1 |
| Profit Margin | -66.82 % |
| Operating Margin | -45.14 % |
| Return on Assets (ttm) | -16.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 16.89 % |
| Gross Profit (p.s.) | 1.58 |
| Sales Per Share | 1.8 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -5.14 |
| PEG Ratio | 0 |
| Price to Book value | -91.34 |
| Price to Sales | 4.55 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|